Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine

Journal of Thoracic Disease, 08/02/2011

Provencio M et al. – Concurrent chemo-radiotherapy improves overall survival of patients with locally advanced NSCLC, compared with sequential chemo-radiotherapy. Platinum-based polychemotherapy is considered the standard treatment. The second drugs associated to platinum seems to have no large impact in survival, so it should be choice based on its toxicity profile. Cisplatin plus vinorelbine regimen is a good candidate for combination with concurrent radiotherapy because of its efficacy and safety. These results are highly promising, being even better than other concurrent chemotherapy studies, with very good tolerance and little toxicity.

Methods

  • Reviewed treatment of inoperable stage III NSCLC and role of concomitant vinorelbine

Results

  • Concurrent chemo-radiotherapy improves OS of patients with locally advanced NSCLC, compared with sequential chemo-radiotherapy
  • Platinum-based polychemotherapy is considered standard treatment
  • Second drugs associated to platinum seems to have no large impact in survival, so it should be choice based on its toxicity profile
  • Cisplatin plus vinorelbine regimen is a good candidate for combination with concurrent radiotherapy because of its efficacy and safety

Print Article Summary Cat 2 CME Report